Sp1 modification of human endothelial nitric oxide synthase promoter increases the hypoxia-stimulated activity

Microvascular Research

Volumn 93, Issue , 2014, Pages 80-86

  Yang, Yunhua ^a   Liu, Song ^a   Fan, Zhenhua ^a   Li, Zhuo ^a   Liu, Jing ^b   Xing, Feiyue ^a  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; LUCIFERASE; MESSENGER RNA; TRANSCRIPTION FACTOR SP1; COBALT; COBALT CHLORIDE; NOS3 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL HYPOXIA; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME MODIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; REGULATORY SEQUENCE; TIME; UPREGULATION;

BASE SEQUENCE; BINDING SITES; CELL HYPOXIA; CELLS, CULTURED; COBALT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MOLECULAR SEQUENCE DATA; NITRIC OXIDE SYNTHASE TYPE III; PROMOTER REGIONS, GENETIC; REGULATORY ELEMENTS, TRANSCRIPTIONAL; SP1 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 84901240756     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2014.03.004     Document Type: Article

References (52)

1. Ago T., et al. Pathophysiological roles of NADPH oxidase/Nox family proteins in the vascular system. Circ. J. 2011, 75:1791-1800.
2. Andrew P.J., Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc. Res. 1999, 43:521-531.
3. Brix B., Mesters J.R., Pellerin L., Johren O. Endothelial cell-derived nitric oxide enhances aerobic glycolysis in astrocytes via HIF-1alpha-mediated target gene activation. J Neurosci. 2012, 32:9727-9735.
4. Channon K.M., et al. Adenoviral gene transfer of nitric oxide synthase: high level expression in human vascular cells. Cardiovasc. Res. 1996, 32:962-972.
5. Chen A.F., et al. Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery. Circ. Res. 1997, 80:327-335.
6. Chen S., et al. Functional role of a conformationally flexible homopurine/homopyrimidine domain of the androgen receptor gene promoter interacting with Sp1 and a pyrimidine single strand DNA-binding protein. Mol. Endocrinol. 1997, 11:3-15.
7. Cho D.H., et al. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPAR gamma-independent signaling pathways. J. Biol. Chem. 2004, 279:2499-2506.
8. Cieslik K., et al. Transcriptional regulation of endothelial nitric-oxide synthase by lysophosphatidylcholine. J. Biol. Chem. 1998, 273:14885-14890.
9. Harrison David G., Inoue Nobutaka, Ohara Yuichi, Fukai Tohru Modulation of endothelial cell nitric oxide synthase expression. Jpn. Circ. J. 1996, 60:815-821.
10. Duran W.N., et al. The NO cascade, eNOS location, and microvascular permeability. Cardiovasc. Res. 2010, 87:254-261.
11. Faber P.W., et al. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J. Biol. Chem. 1993, 268:9296-9301.
12. Farias M., et al. Nitric oxide reduces SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP-C/EBPalpha in human umbilical vein endothelial cells from gestational diabetes. Cardiovasc. Res. 2010, 86:45-54.
13. Ferrero E., et al. Cell food improves respiratory metabolism of endothelial cells and inhibits hypoxia-induced reactive oxygen species (ros) generation. J. Physiol. Pharmacol. 2011, 62:287-293.
14. Fish J.E., et al. Hypoxic repression of endothelial nitric-oxide synthase transcription is coupled with eviction of promoter histones. J. Biol. Chem. 2009, 285:810-826.
15. Forstermann U., et al. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 1998, 12:773-790.
16. Gan Y.Y., Chen C.F. The 27-bp VNTR polymorphism in intron 4 of the human eNOS gene in healthy Singaporean Chinese, Indians, and Malays. Biochem. Genet. 2012, 50:52-62.
17. Hekmatnejad B., et al. Control of Fiat (factor inhibiting ATF4-mediated transcription) expression by Sp family transcription factors in osteoblasts. J. Cell Biochem. 2013.
18. Ho J.J.D., et al. Nitric oxide signaling in hypoxia. J. Mol. Med. 2012, 90:217-231.
19. Hoffmann A., et al. Hypoxia-induced upregulation of eNOS gene expression is redox-sensitive: a comparison between hypoxia and inhibitors of cell metabolism. J. Cell Physiol. 2001, 188:33-44.
20. Ignarro L.J. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J. Physiol. Pharmacol. 2002, 53:503-514.
21. Ignarro L.J., et al. Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol. 1999, 34:879-886.
22. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nat Rev Drug Discov. 2003, 2:803-811.
23. Karantzoulis-Fegaras F., et al. Characterization of the human endothelial nitric-oxide synthase promoter. J. Biol. Chem. 1999, 274:3076-3093.
24. Kawashima S. Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis. Journal of Pharmacological Sciences. 2004, 96:411-419.
25. Koshiji M., To K.K., Hammer S., Kumamoto K., Harris A.L., et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell. 2005, 17:793-803.
26. Kumar S., et al. Hydrogen peroxide decreases endothelial nitric oxide synthase promoter activity through the inhibition of AP-1 activity. Am J Physiol Lung Cell Mol. Physiol. 2008, 295:L370-L377.
27. Li H., et al. Flavonoids from artichoke (Cynara scolymus L.) up-regulate endothelial-type nitric-oxide synthase gene expression in human endothelial cells. J. Pharmacol. Exp. Ther. 2004, 310:926-932.
28. Li J., et al. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc. Res. 2007, 77:169-177.
29. Li N., Seetharam B. A 69-base pair fragment derived from human transcobalamin II promoter is sufficient for high bidirectional activity in the absence of a TATA box and an initiator element in transfected cells. Role of an E box in Transcriptional Activity. J. Biol. Chem. 1998, 273:28170-28177.
30. Liu Y.X., et al. Protective effect of alpha-lipoic acid on oxidized low density lipoprotein-induced human umbilical vein endothelial cell injury. Pharmacol. Rep. 2011, 63:1180-1188.
31. Marsden P.A., et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J. Biol. Chem. 1993, 268:17478-17488.
32. Mazure N.M., Brahimi-Horn M.C., Berta M.A., Benizri E., Bilton R.L., et al. HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem. Pharmacol. 2004, 68:971-980.
33. Min J., et al. Hypoxia-induced endothelial NO synthase gene transcriptional activation is mediated through the tax-responsive element in endothelial cells. Hypertension. 2006, 47:1189-1196.
34. Miyake T., et al. Endothelial nitric oxide synthase plays a main role in producing nitric oxide in the superacute phase of hepatic ischemia prior to the upregulation of inducible nitric oxide synthase. J. Surg. Res 2013, 10.1016/j.jss.2013.01.048.
35. Moncada S., et al. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43:109-142.
36. Moon J., et al. Lack of evidence for contribution of Glu298Asp (G894T) polymorphism of endothelial nitric oxide synthase gene to plasma nitric oxide levels. Thromb. Res. 2002, 107:129-134.
37. Mukhopadhyay D., et al. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 1997, 17:5629-5639.
38. Muta K., et al. Gene expression of nitric oxide synthase and heme oxygenase in placental villi during pregnancy with and without intrauterine growth restriction. J. Clin. Biochem. Nutrition. 2002, 32:11-21.
39. Nakayama M., et al. Repression of heme oxygenase-1 by hypoxia in vascular endothelial cells. Biochem Biophys Res Commun. 2000, 271:665-671.
40. Napoli C., Ignarro L.J. Nitric oxide and atherosclerosis. Nitric. Oxide. 2001, 5:88-97.
41. Palmer R.M.J., et al. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature. 1988, 333:664-666.
42. Qiao W., et al. Endothelial nitric oxide synthase as a marker for human endothelial progenitor cells. Tohoku J. Exp. Med. 2010, 221:19-27.
43. Suske G. The Sp-family of transcription factors. Gene 1999, 238:291-300.
44. Suwaidi J.A., et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000, 101:948-954.
45. Takeishi Y. The nitric oxide synthase family and left ventricular diastolic function. Circ. J. 2010, 74:2556-2557.
46. Tang J.L., et al. Role of Sp1 in transcriptional activation of human nitric oxide synthase type III gene. Biochem. Biophys. Res. Commun. 1995, 213:673-680.
47. Wariishi S., et al. A SP1 binding site in the GC-rich region is essential for a core promoter activity of the human endothelial nitric oxide synthase gene. Biochem. Biophys. Res. Commun. 1995, 216:729-735.
48. Werns S.W., et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation. 1989, 79:287-291.
49. Wu K.K. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann. NY. Acad. Sci. 2002, 962:122-130.
50. Xiao J., et al. eNOS correlates with mitochondrial biogenesis in hearts of congenital heart disease with cyanosis. Arq. Bras. Cardiol. 2012, 99:780-788.
51. Yan-yan L. Endothelial nitric oxide synthase G894T gene polymorphism and essential hypertension in the Chinese population: a meta-analysis involving 11,248 subjects. Int. Med. 2011, 50:2099-2106.
52. Zhang E., et al. Effect of all-trans-retinoic acid on the development of chronic hypoxia-induced pulmonary hypertension. Circ. J. 2010, 74:1696-1703.